Receptor variation influences fingolimod efficacy in mouse multiple sclerosis models
Multiple sclerosis (MS) is an autoimmune disorder that results in demyelination of neurons. The FDA-approved drug fingolimod (Gilenya, FTY-720) modulates signaling by the bioactive lipid sphingosine-1-phosphate (S1P), which ...
Jun 16, 2016
0
0